-
Featured Authors
-
Archives
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: BIOTECH
A Bright Future for Orphan Disease Indications
In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals). Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >
Putting a Ring on It: Advice on Successful Drug Development Collaborations
Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears. At BIO’s recent CEO & Investor Conference, a panel of industry veterans gathered to discuss best practices in drug development partnering. Moderated by Jeff Stewart, Senior Engagement Manager with Campbell Alliance, the panel “Putting a Ring on it: When Drug Development Partnerships Read More >
Thoughts on the President’s State of the Union
I had several thoughts watching President Obama’s State of the Union Address tonight. First, we at BIO remain concerned about the possible impact that sequestration may have – specifically the potential impact it may have on human health. There are millions of patients – all hopeful that new treatments will become available soon. Our fear is that sequestration may impact the ability of those patients to access new treatments in a timely manner. That fear Read More >
Governor Quinn Invites Biotech Professionals to Chicago
Governor Pat Quinn has long been a champion of the bioscience industry – both for its promise to help solve the world’s most pressing problems and as a means of elevating the economic development prospects for his state. The Governor has consistently championed educational reform, entrepreneurship, intellectual property protection, and industry regulation based on rigorous science. That is why he was named BIO’s Governor of the Year in 2011. We are furthermore honored that he Read More >
Anti-Biotech Activist Changes Sides: “I discovered science”
If you missed last week’s report from the Oxford Farming Conference, Mark Lynas, the British writer and environmentalist who once helped drive Europe’s movement against biotech crops, apologized for those actions and embraced the technology as a vital tool for ending hunger and conserving the environment. The change of heart was widely reported in many mainstream outlets such as The New York Times, Los Angeles Times, Forbes, Discover magazine, Slate magazine and Science 2.0, among others. Read More >
